New pill could replace shots for Kidney-Related anemia

NCT ID NCT07487727

Recruiting now Disease control Sponsor: Kind Pharmaceuticals LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests an oral drug called AND017 against standard injected ESA therapy for anemia in people with chronic kidney disease who are not on dialysis. About 240 participants will receive either AND017 or ESA to see which better maintains healthy hemoglobin levels over 27 weeks. The goal is to find a more convenient treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AND017 (oral capsule)
What this could lead to: If successful, AND017 could offer a more convenient oral treatment option for anemia in chronic kidney disease patients who do not need dialysis.
What could go wrong: This is a Phase 3 trial, but results may not confirm superiority or safety over existing treatments. Side effects and individual responses vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates